in this issue
Regions :: North America :: U.S.
Lonza and BioWa sign licensing agreement with AstraZeneca
2:09 PM MST | December 11, 2013 | Deepti Ramesh
Lonza and BioWa (La Jolla, CA), a wholly owned subsidiary of biopharmaceutical company Kyowa Hakko Kirin (Tokyo), have entered into a licensing agreement with MedImmune (Gaithersburg, MD), the global biologics R&D arm of AstraZeneca (London). MedImmune has licensed the companies’ Potelligent CHOK1SV cell line technology for use in multiple proprietary antibodies in its pipeline. MedImmune entered into a previous licensing agreement with BioWa in 2007 for Potelligent technology. Today’s agreement incorporates Lonza’s technology to the...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee